December 14, 2024 18:36 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Pushpa 2 stampede: Allu Arjun walks out of jail, actor's lawyer slams delay in release | Donald Trump intends to end 'inconvenient' and 'very costly' Daylight Saving Time | Suchir Balaji: Indian-origin former OpenAI researcher found dead at US apartment | Bengaluru techie suicide: Karnataka Police issues summons to wife Nikita, her family members | French President Macron appoints centrist leader Francois Bayrou as new Prime Minister | Congress always prioritised personal interest over Constitution: Rajnath Singh | Jaishankar calls attack on Hindus in Bangladesh 'a source of concern' | Allu Arjun arrested over woman's death in stampede during Pushpa 2 premiere show | RBI receives bomb threat in Russian language, case filed | UP teenager kills mother, lives with body for 5 days
DCGI approves Tata Group's low cost CRISPR Covid-19 test 'Feluda'

DCGI approves Tata Group's low cost CRISPR Covid-19 test 'Feluda'

Sep 21, 2020, at 07:55 am

Delhi/IBNS: The Drugs Controller General of India (DCGI) has given its approval for the commercial launch of India's first Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), Covid-19 test 'Feluda' developed by the Tata Group and CSIR-IGIB (Institute of Genomics and Integrative Biology).